WHO Issues Alert Over Acute Lack of Weight-Loss Medications

Fewer than a tenth of patients that would benefit from weight-loss injections including Wegovy are able to get them, warns the World Health Organization as it publishes its first guidance on the therapies.

Given more than one billion individuals worldwide currently living with obesity, it is calling for increased and just availability to these injectable treatments.

Per forecasts, over two billion could be living with obesity by 2030 without intervention.

"Our latest guidelines recognises that excess weight is a chronic disease that can be managed with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the jabs that can assist patients in reducing considerable body mass, explains the organization.

Skinny Jab Supply Crisis

Even under the current best projected case, the production of such drugs would only suffice for about 100 million people – less than 10% of eligible patients, per the WHO.

The advice encourages governments and firms to widen availability, through strategies including licensing agreements.

A patent on a key compound – the core component of a leading brand – is due to expire in several nations in 2026.

The Way Weight-Loss Drugs Function

The injections imitate a biological compound to slow digestion, suppress the appetite and increase satiety so users consume fewer calories.

Patients typically begin shedding pounds within a few weeks of beginning the weekly injections.

Research suggests people may see weight return within a year of halting the medication, because their usual food cravings return.

To be overweight or obese raises your risk for experiencing diseases, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.

Obesity affects individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.